



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Edarbi™

Common Name: Azilsartan

PDL Category: Angiotensin Receptor Blocker

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Benicar®	Preferred with Conditions
Cozaar®	Preferred with Conditions
Diovan®	Preferred with Conditions

Summary

Indications and Usage: Treatment of hypertension in adults, either alone or in combination with other antihypertensive agents.¹

Mechanism of Action: Blocks the action of angiotensin II, a vasopressor hormone.¹

Dosage Forms: Tablets; 40mg and 80mg¹

Recommended Dosage: 80mg once daily. May consider a dose of 40mg once daily in patients being treated with high dose diuretics.¹

Common Adverse Drug Reactions: Diarrhea¹

Contraindications: None¹

Manufacturer: Takeda Pharmaceuticals America, Inc.

Analysis: Edarbi™ is a new angiotensin receptor blocker (ARB) indicated for the treatment of hypertension in adults. In the trials used to gain FDA approval, Edarbi™ 80mg lowered blood pressure by approximately 3-4mmHg over olmesartan and valsartan, respectively. Edarbi™ was shown to have sustained antihypertensive effect with no rebound effect after long-term treatment. There are no trials with Edarbi™ establishing improved cardiovascular outcomes in patients with hypertension. In addition, hypertension is the only approved indication. Preferred alternatives exist on the PDL which are more cost effective for the treatment of hypertension, indicated for pediatric use, and have established cardiovascular benefits. Although clinical trials suggest there are some greater effects seen with Edarbi™ compared to olmesartan and valsartan, there is no evidence to support Edarbi™ is more efficacious than all other medications currently available for the treatment of hypertension. It is recommended that Edarbi™ be added to the Preferred Drug List as a non-preferred drug with conditions.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug with Conditions	<input type="checkbox"/> Refer to DUR for PA criteria

1. Edarbi™ [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.